South African Gastroenterology Review - Volume 7, Issue 2, 2009
Volume 7, Issue 2, 2009
Author Sandie ThomsonSource: South African Gastroenterology Review 7 (2009)More Less
I write this editorial just prior to dropping off the SAGES council radar. I have enjoyed my time on council and will miss the camaraderie of the Society and its council members past and present. A Society which does the most for its members on all the many Societies I have served on during my time in South Africa. Please continue the good work, it is easy with Karin Fenton aboard the ship.
Source: South African Gastroenterology Review 7, pp 6 –9 (2009)More Less
In South-Africa nurses and doctors are emigrating in significant numbers. Job satisfaction, safety and ensuring career progression are important in retaining doctors to make a career in RSA. Due to budgetary constraints many hospitals have not been upgraded. Coming home after overseas training seems difficult. In RSA it takes a minimum of 13 years for a young specialist to get on the register and 15 years for subspecialists. Career progression, creating more specialist trainees in public and private hospitals and shortening the period of professional training are potential solutions to the problem. India with a population of more than 1 billion people is struggling with similar problems. For the past 10-15 years private hospitals have assisted in manpower development for medical specialist and subspecialist careers. Currently their private sector trains 60% of their recognised (sub)specialities fellows.
A national task force for specialist training in RSA should be instituted. It should discuss, based on the current status and projected specialist and subspecialist personnel requirements, the future structure and logistics of training needs. This is required in all subspecialities including gasteroenterology, as has been done in India. It is hoped that as a consequence well-trained doctors, like in India, might move to provincial hospitals in rural areas, uplifting the medical services and keeping medical power in South-Africa. South-Africa should become a model for Sub-Saharan Africa, as India already is for South-East Asia.
Source: South African Gastroenterology Review 7, pp 11 –13 (2009)More Less
Source: South African Gastroenterology Review 7, pp 15 –17 (2009)More Less
SAGES clinical guidelines : Anti-tumour necrosis factor antibodies (Anti-TNF) in inflammatory bowel disease : guidelinesSource: South African Gastroenterology Review 7, pp 19 –20 (2009)More Less
Author Andy GirdwoodSource: South African Gastroenterology Review 7 (2009)More Less
When I heard about the TriNations meeting being held in New Zealand I was determined to go. I have always wanted to go to New Zealand but one has to have a good reason to go there. My mind was made up when Jake Krige had to turn down his invitation and suggested that I take on his well established role as the quiz master in the TriNations quiz. It was going to be a hard act to follow but I was offered accommodation and registration and accepted gleefully. The congress was held at Millbrook, a beautiful Japanese owned golf estate 17 kilometres outside of Queenstown, the adventure capital of South Island.
SAGES clinical practice guidelines on the use of intravenously administered proton pump inhibitors (PPI) : guidelinesSource: South African Gastroenterology Review 7 (2009)More Less
Clinical situations in which intravenously administered PPI may be appropriate are
- Hypersecretory states.
- Gastro-oesophageal reflux disease in patients unable to take by mouth or swallow.
- Upper gastro-intestinal haemorrhage.
A meta-analysis of 21 randomised controlled trials evaluating proton pump inhibitors for bleeding ulcers (with or without endoscopic therapy) found a significant reduction in the risk of rebleeding (OR 0.40, 95 % CI 0.33 - 0.64) and the need for surgery (OR 0.59, 95 % CI 0.46 - 0.76) but no effect on mortality.
Author Reid AllySource: South African Gastroenterology Review 7 (2009)More Less
Prof Quigley gave an overview of probiotics ... The term, was first coined by Metchnikoff in 1908, to describe live microbial food ingredients that alter gut microflora and confer good health. These "good" bacteria by means of its byproducts such as SCFA, bile salt metabolites, bacteriocins, neuro peptides and gas alter the host mucosal immunity by its antibacterial actions, its ability to enhance barrier function and motility, by modulating cytokine and immune cells and by producing valuable metabolites.
Revellex® (infliximab) now indicated for ulcerative colitis and paediatric crohn's disease : product newsSource: South African Gastroenterology Review 7, pp 28 –29 (2009)More Less
Revellex® (infliximab) is a monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α), which has been shown to play a role in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, paediatric Crohn's disease, psoriatic arthritis, and plaque psoriasis. Revellex is the global market leader among anti-TNF-α therapies and was the first agent approved for the treatment of both ulcerative colitis and Crohn's disease.
Author S. GroblerSource: South African Gastroenterology Review 7, pp 30 –31 (2009)More Less
Author Mashiko SetshediSource: South African Gastroenterology Review 7 (2009)More Less
I've always known that I wanted to do some type of research, but I didn't know how to go about it or if I'd do well in it. After years of clinical training I decided it was time (albeit late in my opinion) to get exposed to basic science research to try to broaden my skills. My supervisor Professor Kew arranged for me to join one of his collaborators (Dr Wands) who is the director of the Liver Research Center at the Medical School of Brown University in Providence, Rhode Island.